1 / 10

Side-effects and Potential Risks for CART Cell Therapy

Chimeric antigen receptor (CAR) is a recombinant immunoreceptor combining an antibody-derived targeting fragment with signaling domains capable of activating cells, which endows T cells with the ability to recognize tumor-associated surface antigens independent of the expression of major histocompatibility complex (MHC) Molecules. Despite the promising therapeutic effects of CAR T therapy, there still has several several-sided that needs to get through.<br>

bellasmith123
Télécharger la présentation

Side-effects and Potential Risks for CART Cell Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Side-effects and Potential Risks for CART Cell Therapy www.creative-biolabs.com/car-t

  2. Chimeric antigen receptor (CAR) is a recombinant immunoreceptor combining an antibody-derived targeting fragment with signaling domains capable of activating cells, which endows T cells with the ability to recognize tumor-associated surface antigens independent of the expression of major histocompatibility complex (MHC) Molecules. Despite the promising therapeutic effects of CAR T therapy, there still has several several-sided that needs to get through.

  3. CRS Off-target effect Tumor lysis syndrome Other side-effects CONTENTS

  4. CRS is one of the common side-effects to CART cell therapy. CRS is a non-antigen-specific toxicity caused by high-level immune activation and is associated with an increase in circulating levels of cytokines including IL-6 and IFN-γ. CRS

  5. Because CART cells have high affinity with tumor-associated antigens and are related antigens for tumors, when they are combined with tumor-associated antigens expressed by normal tissues, they cause toxic reactions to normal tissues, which are called off-target effects. Off-target effect

  6. The occurrence of tumor lysis syndrome is related to the excessive T cell proliferation in patients, the death of tumor cells after treatment, and the release of a large number of cytokines. Alkalinization, hydration, and drug remission can be used. Tumor lysis syndrome

  7. In clinical trials of CD19-CART cell therapy, there are some rare side-effects. Brentjens et al. reported that one patient developed high fever and wheezing 24 hours after receiving cell therapy, followed by renal insufficiency. The patient died after 44 hours of CART cell input. Kochenderfer et al. reported that 1 patient developed pulmonary infection 18 days after the entry of CART cells, infected with influenza virus, and eventually died. Other side-effects

  8. About Creative Biolabs As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Additionally, we also offer an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, we have built up a unique unparalleled CAR construction and production platform for all four CAR generations.

  9. Contact us 45-1 Ramsey Road, Shirley, NY 11967, USA Email: marketing@creative-biolabs.com

  10. Thank you

More Related